Cable Hill Partners’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Cable Hill Partners’s Portfolio PTLA Stock Details PTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-140	Closed	-$4K	–	970
2016 Q2	$4K	Hold	140	–	–	﹤0.01%	570
2016 Q1	$3K	Sell	140 -110	-44%	-$3.49K	﹤0.01%	574
2015 Q4	$13K	Hold	250	–	–	0.01%	315
2015 Q3	$12K	Hold	250	–	–	0.01%	342
2015 Q2	$12K	Hold	250	–	–	0.01%	409
2015 Q1	$10K	Buy	250 +7	+3%	+$240	0.01%	444
2014 Q4	$7K	Buy	+243	New	+$6.75K	0.01%	504

Other funds holding PTLA

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Cable Hill Partners's PTLA Position: Q3 2016 in Review

Cable Hill Partners sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q3 2016, closing a stake of 140 shares — an estimated $4K sold.

Cable Hill Partners first reported a position in PTLA in Q4 2014 and held it in 7 quarters. The position peaked at $13K in Q4 2015. 151 funds tracked by Wall St. Rank hold PTLA as of Q3 2016.

Cable Hill Partners reported no remaining Portola Pharmaceuticals, Inc. position as of Q3 2016 after selling out during the quarter.
Cable Hill Partners sold 140 Portola Pharmaceuticals, Inc. shares in Q3 2016, an estimated $4K.
Cable Hill Partners first reported a position in Portola Pharmaceuticals, Inc. in Q4 2014 and held it in 7 quarters.
Cable Hill Partners's Portola Pharmaceuticals, Inc. position peaked at $13K in Q4 2015.
151 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q3 2016.

Based on Cable Hill Partners's 13F filing for Q3 2016, filed 16 Nov 2016.